{"id":62293,"date":"2021-04-26T13:01:58","date_gmt":"2021-04-26T11:01:58","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/"},"modified":"2025-10-13T15:32:42","modified_gmt":"2025-10-13T13:32:42","slug":"disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/","title":{"rendered":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington"},"content":{"rendered":"<p><strong>En menos de 12 meses, la colaboraci\u00f3n entre la compa\u00f1\u00eda <a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/chemotargets\/\" target=\"_blank\" rel=\"noopener noreferrer\">Chemotargets<\/a>, con sede en el Parc Cient\u00edfic de Barcelona, y la startup norteamericana <a href=\"https:\/\/galyan-bio.com\/\" target=\"_blank\" rel=\"noopener noreferrer\">Galyan Bio<\/a>, ubicada en Berkeley (California), ha generado el primer candidato cl\u00ednico dise\u00f1ado con inteligencia artificial para el dif\u00edcil \u00e1mbito de las patolog\u00edas neurodegenerativas. Se trata de un f\u00e1rmaco<em> first-in-class<\/em> (con un mecanismo de acci\u00f3n totalmente innovador) para la enfermedad de Huntington (MH), que se prev\u00e9 que inicie los ensayos cl\u00ednicos en 2022.<\/strong><\/p>\n<p>En colaboraci\u00f3n con Galyan Bio, Chemotargets emple\u00f3 sus m\u00e9todos de dise\u00f1o <em>de novo<\/em> de f\u00e1rmacos basados en inteligencia artificial (IA) para identificar r\u00e1pidamente nuevas mol\u00e9culas capaces de modular la actividad de dianas que previamente no se contemplaban como farmacol\u00f3gicamente tratables.<\/p>\n<p>La enfermedad de Huntington es un trastorno neurodegenerativo de origen gen\u00e9tico que afecta a miles de pacientes en todo el mundo. Actualmente no tiene curaci\u00f3n, \u00fanicamente existen terapias dirigidas a paliar sus s\u00edntomas, algunas con procedimientos muy invasivos. El nuevo tratamiento oral dise\u00f1ado per Chemotargets y Galyan Bio pretende retardar la patolog\u00eda en los pacientes sintom\u00e1ticos y retrasar la manifestaci\u00f3n en los portadores del gen sin s\u00edntomas.<\/p>\n<p>\u00abEl desarrollo de nuevas mol\u00e9culas mediante la qu\u00edmica m\u00e9dica siempre ha sido un proceso laborioso y costoso. Hemos utilizado las plataformas de descubrimiento de f\u00e1rmacos de Chemotargets para acelerar considerablemente este proceso. En base a dise\u00f1os <em>de novo<\/em> impulsados por IA, Chemotargets realiz\u00f3 una selecci\u00f3n de mol\u00e9culas, 49 de las cuales Galyan Bio prob\u00f3 experimentalmente. Nuestras expectativas se superaron con creces, puesto que identificamos 6 compuestos que pod\u00edan unirse realmente a nuestra diana farmacol\u00f3gica. La optimizaci\u00f3n de uno de estos compuestos ha dado lugar a un candidato a f\u00e1rmaco precl\u00ednico para la MH\u00bb, explica el <strong>Dr. Simon Marius Galyan<\/strong>, director general de Galyan Bio.<\/p>\n<p>ProSurfScan, la plataforma propia de dise\u00f1o de f\u00e1rmacos <em>de<\/em> <em>novo<\/em> de Chemotargets basada en IA, utiliza nuevos procedimientos de exploraci\u00f3n agn\u00f3stica de la prote\u00edna diana para realizar un cribado virtual basado en fragmentos de todas las posibles \u00e1reas de uni\u00f3n a f\u00e1rmacos. A continuaci\u00f3n, los fragmentos se unen autom\u00e1ticamente para dise\u00f1ar mol\u00e9culas de uni\u00f3n eficaces. Estos m\u00e9todos son especialmente adecuados para dianas nuevas, dif\u00edciles y no abordables anteriormente, as\u00ed como para dianas farmacol\u00f3gicas para las que se requiere una alta selectividad de isoformas.<\/p>\n<p>ProSurfScan forma parte de un paquete completo de herramientas de descubrimiento de f\u00e1rmacos basadas en IA que se utilizan de manera habitual en Chemotargets y que incluyen <a href=\"https:\/\/www.chemotargets.com\/Chemotargets-CLARITY\" target=\"_blank\" rel=\"noopener noreferrer\">CLARITY<sup>\u00ae<\/sup><\/a>\u00a0(<a href=\"https:\/\/www.chemotargets.com\/News\/id\/99\/chemotargets-clarity-has-been-awarded-the-seal-of-excellence-from-the-european-commission\" target=\"_blank\" rel=\"noopener noreferrer\">Seal of Excellence<\/a> de la Comisi\u00f3n Europea), la plataforma de software l\u00edder del sector para anticipar la seguridad de las nuevas mol\u00e9culas de f\u00e1rmacos. La licencia de esta tecnolog\u00eda fue adquirida en 2020 por la<a href=\"https:\/\/www.chemotargets.com\/News\/id\/40\/new-research-collaboration-agreement-(rca)-between-the-fda-cder-(center-for-drug-evaluation-and-research)-and-chemotargets-sl\" target=\"_blank\" rel=\"noopener noreferrer\"> U.S. Food and Drug Administration (FDA)<\/a>, entre otras organizaciones, y se usa actualmente en muchas de las principales farmac\u00e9uticas del mundo.<\/p>\n<p>\u00abEstamos absolutamente encantados de haber contribuido eficazmente a la obtenci\u00f3n de un candidato a f\u00e1rmaco innovador para la enfermedad de Huntington. Tener una prueba tangible de que nuestros dise\u00f1os <em>de novo<\/em> conducen a peque\u00f1as mol\u00e9culas bioactivas progresables en un proyecto de descubrimiento de f\u00e1rmacos lo es todo para nosotros. Esto significa que nuestra plataforma <em>in silico<\/em> est\u00e1 preparada para abordar otras prote\u00ednas diana nuevas y dif\u00edciles, para las cuales no existen modalidades terap\u00e9uticas\u00bb, apunta el <strong>Dr. Jordi Mestres<\/strong>, fundador y actual director cient\u00edfico de Chemotargets.<\/p>\n<p>\u00abAnte todo, estamos agradecidos por la oportunidad de contribuir a una posible alternativa terap\u00e9utica para los pacientes de la enfermedad de Huntington. Francamente, no me sorprenden los resultados de la actividad experimental de las mol\u00e9culas resultantes del dise\u00f1o <em>de novo<\/em>. ProSurfScan ha demostrado repetidamente su capacidad para dise\u00f1ar mol\u00e9culas nuevas y selectivas que se unen a dianas nuevas y dif\u00edciles en nuestros programas internos y, sin duda, continuar\u00e1 haci\u00e9ndolo\u201d, a\u00f1ade.<\/p>\n<p>Aunque la inteligencia artificial es necesaria en casi todo lo que llevamos a cabo en Chemotargets, somos una empresa centrada en ayudar a los pacientes. Al utilizar la IA para ayudar a la toma de decisiones en el dise\u00f1o y el desarrollo de nuevas terapias, nuestra misi\u00f3n ser\u00e1 siempre facilitar el desarrollo de terapias m\u00e1s seguras y eficaces en menos tiempo y con un coste inferior al del pasado. Nos complace que, en el caso de los pacientes con la enfermedad de Huntington, hayamos podido demostrar este potencial\u00bb, declara el <strong>Dr. Scott Boyer<\/strong>, director general de Chemotargets.<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>En menos de 12 meses, la colaboraci\u00f3n entre la compa\u00f1\u00eda Chemotargets, con sede en el Parc Cient\u00edfic de Barcelona, y la startup norteamericana Galyan Bio, ubicada en Berkeley (California), ha&#8230;<\/p>\n","protected":false},"author":4,"featured_media":62207,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[],"class_list":["post-62293","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"En menos de 12 meses, la colaboraci\u00f3n entre la compa\u00f1\u00eda Chemotargets, con sede en el Parc Cient\u00edfic de Barcelona, y la startup norteamericana Galyan Bio, ubicada en Berkeley (California), ha...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-26T11:01:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:32:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"589\" \/>\n\t<meta property=\"og:image:height\" content=\"276\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Azucena Berea\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Azucena Berea\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/\"},\"author\":{\"name\":\"Azucena Berea\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"headline\":\"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington\",\"datePublished\":\"2021-04-26T11:01:58+00:00\",\"dateModified\":\"2025-10-13T13:32:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/\"},\"wordCount\":797,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/De-novo-drug-design_Chemotargets.jpg\",\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/\",\"name\":\"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/De-novo-drug-design_Chemotargets.jpg\",\"datePublished\":\"2021-04-26T11:01:58+00:00\",\"dateModified\":\"2025-10-13T13:32:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/De-novo-drug-design_Chemotargets.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2021\\\/04\\\/De-novo-drug-design_Chemotargets.jpg\",\"width\":589,\"height\":276},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/810a86a39effe6bf90f9ab918ca43239\",\"name\":\"Azucena Berea\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g\",\"caption\":\"Azucena Berea\"},\"sameAs\":[\"https:\\\/\\\/www.pcb.ub.edu\"],\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/aberea\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/","og_locale":"es_ES","og_type":"article","og_title":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona","og_description":"En menos de 12 meses, la colaboraci\u00f3n entre la compa\u00f1\u00eda Chemotargets, con sede en el Parc Cient\u00edfic de Barcelona, y la startup norteamericana Galyan Bio, ubicada en Berkeley (California), ha...","og_url":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2021-04-26T11:01:58+00:00","article_modified_time":"2025-10-13T13:32:42+00:00","og_image":[{"width":589,"height":276,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg","type":"image\/jpeg"}],"author":"Azucena Berea","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Azucena Berea","Tiempo de lectura":"4 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/"},"author":{"name":"Azucena Berea","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"headline":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington","datePublished":"2021-04-26T11:01:58+00:00","dateModified":"2025-10-13T13:32:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/"},"wordCount":797,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg","articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/","url":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/","name":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg","datePublished":"2021-04-26T11:01:58+00:00","dateModified":"2025-10-13T13:32:42+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2021\/04\/De-novo-drug-design_Chemotargets.jpg","width":589,"height":276},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/disenan-el-primer-farmaco-con-inteligencia-artificial-para-la-enfermedad-de-huntington\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"Dise\u00f1an el primer f\u00e1rmaco con inteligencia artificial para la enfermedad de Huntington"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/810a86a39effe6bf90f9ab918ca43239","name":"Azucena Berea","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/32577545a82a87a5c7e06fb02f02362edb2f379afdb4c8b5783d81635141181f?s=96&d=mm&r=g","caption":"Azucena Berea"},"sameAs":["https:\/\/www.pcb.ub.edu"],"url":"https:\/\/www.pcb.ub.edu\/es\/author\/aberea\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/62293","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=62293"}],"version-history":[{"count":4,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/62293\/revisions"}],"predecessor-version":[{"id":62297,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/62293\/revisions\/62297"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/62207"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=62293"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=62293"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=62293"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}